Glassman Sees `Fine Line' for Off-Label Drug Marketing: Video

Nov. 9 (Bloomberg) -- Robert Glassman, private equity partner at OrbiMed Advisors, talks with Blo...  More »

Nov. 9 (Bloomberg) -- Robert Glassman, private equity partner at OrbiMed Advisors, talks with Bloomberg's Erik Schatzker and Deirdre Bolton about the practice of so-called off-label drug marketing and its impact on the industry. Since May 2004, Pfizer Inc., Eli Lilly & Co., Bristol-Myers Squibb Co. and four other drug companies have paid a total of $7 billion in fines and penalties. Six of the companies admitted in court that they marketed medicines for unapproved uses. (Source: Bloomberg)  « Less